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Axicabtagene Ciloleucel CAR T-Cell Therapy
in Refractory Large B-Cell Lymphoma
S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D.B. Miklos, C.A. Jacobson,
I. Braunschweig, O.O. Oluwole, T. Siddiqi, Y. Lin, J.M. Timmerman, P.J. Stiff,
J.W. Friedberg, I.W. Flinn, A. Goy, B.T. Hill, M.R. Smith, A. Deol, U. Farooq,
P. McSweeney, J. Munoz, I. Avivi, J.E. Castro, J.R. Westin, J.C. Chavez, A. Ghobadi,
K.V. Komanduri, R. Levy, E.D. Jacobsen, T.E. Witzig, P. Reagan, A. Bot, J. Rossi,
L. Navale, Y. Jiang, J. Aycock, M. Elias, D. Chang, J. Wiezorek, and W.Y. Go

A BS T R AC T
BACKGROUND

In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory
large B-cell lymphoma after the failure of conventional therapy.
METHODS

In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell
lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body
weight after receiving a conditioning regimen of low-dose cyclophosphamide and
fludarabine. The primary end point was the rate of objective response (calculated as
the combined rates of complete response and partial response). Secondary end points
included overall survival, safety, and biomarker assessments.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr.
Neelapu at the University of Texas M.D.
Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, TX 77030, or at sneelapu@
mdanderson.org.
Drs. Neelapu and Locke contributed equally to this article.
This article was published on December 10,
2017, at NEJM.org.
N Engl J Med 2017;377:2531-44.
DOI: 10.1056/NEJMoa1707447
Copyright © 2017 Massachusetts Medical Society.

RESULTS

Among the 111 patients who were enrolled, axi-cel was successfully manufactured
for 110 (99%) and administered to 101 (91%). The objective response rate was 82%,
and the complete response rate was 54%.With a median follow-up of 15.4 months,
42% of the patients continued to have a response, with 40% continuing to have a
complete response. The overall rate of survival at 18 months was 52%. The most common adverse events of grade 3 or higher during treatment were neutropenia (in
78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3
or higher cytokine release syndrome and neurologic events occurred in 13% and
28% of the patients, respectively. Three of the patients died during treatment. Higher
CAR T-cell levels in blood were associated with response.
CONCLUSIONS

In this multicenter study, patients with refractory large B-cell lymphoma who received
CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic
events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy
Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216.)
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arge B-cell lymphomas, including
diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed
follicular lymphoma, are treated with combination
chemoimmunotherapy at diagnosis.1-3 Patients who
have a relapse with chemotherapy-sensitive disease may be treated with high-dose chemotherapy
followed by autologous stem-cell transplantation.1-3
However, patients who have disease that is resistant to primary or salvage chemoimmunotherapy
or who have had a relapse after transplantation
have an extremely poor prognosis.4-13 Recently, in
a large, international, retrospective research study
involving patients with non-Hodgkin’s lymphoma
(SCHOLAR-1), investigators found an objective
response rate of 26%, a complete response rate
of 7%, and a median overall survival of 6.3 months
with existing therapies among patients who had
aggressive B-cell lymphoma that was resistant
to chemotherapy or who had a relapse within
12 months after autologous stem-cell transplantation.14
Single-institution studies of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy have
shown high response rates in refractory B-cell
lymphomas after the failure of conventional therapy.15-19 Investigators at the National Cancer Institute have found that many responses have been
ongoing beyond 4 years, which suggests that this
therapy may be potentially curative.15-17 Axicabtagene ciloleucel (axi-cel, Kite Pharma) is an autologous anti-CD19 CAR T-cell therapy that uses the
same CAR construct that was developed at the
National Cancer Institute.15-17,20 It consists of a
single-chain variable fragment extracellular domain targeting CD19 proteins with CD3ζ (also
called CD247) and CD28 intracellular domains that
signal T-cell activation.20 In this therapy, T cells
that have been removed from a patient are genetically engineered to express anti-CD19 CARs and
are then injected back into the patient.
A phase 1 multicenter study (ZUMA-1) involving seven patients with refractory large B-cell
lymphoma showed that axi-cel could be centrally
manufactured and safely administered.21 An overall response to axi-cel therapy was reported in five
patients and a complete response in four patients,
with an ongoing complete response in three patients reported at 1 year.21 Here, we report the
results of the primary analysis of phase 2 of
ZUMA-1 and an updated analysis with 1 year of
follow-up.
2532
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Me thods
Patients and Study Design

The study was approved by the institutional review board at each study site and was conducted
in accordance with the Good Clinical Practice
guidelines of the International Conference on
Harmonisation. All the patients provided written informed consent. The study was designed
by employees of Kite Pharma, which also paid
for medical-writing support. All the authors discussed and interpreted the results and vouch for
the completeness and accuracy of the data and
analyses and for the adherence of the study to
the protocol, available with the full text of this
article at NEJM.org. All the authors contributed
to the conduct of the study, data analyses, and
writing of the manuscript.
The phase 2 treatment portion of the study
ran from November 2015 through September
2016 at 22 study centers (21 in the United States
and 1 in Israel). (A complete list of study sites is
provided in the Supplementary Appendix, available at NEJM.org.) Follow-up to evaluate the
duration of response, survival, and late adverse
events is ongoing.
All the patients had histologically confirmed
large B-cell lymphoma, including diffuse large
B-cell lymphoma (cohort 1) and primary mediastinal B-cell lymphoma or transformed follicular
lymphoma (cohort 2), on the basis of the 2008
World Health Organization guidelines.22 Central
confirmation of the diagnosis was performed
retrospectively. Patients had refractory disease,
which was defined as progressive or stable disease as the best response to the most recent
chemotherapy regimen or disease progression or
relapse within 12 months after autologous stemcell transplantation. Eligibility criteria and therapy were similar to those in the phase 1 study
(see the Methods section in the Supplementary
Appendix).21
After leukapheresis and axi-cel manufacturing, patients received fixed low-dose conditioning chemotherapy consisting of fludarabine (at a
dose of 30 mg per square meter of body-surface
area per day) and cyclophosphamide (at a dose
of 500 mg per square meter per day) on days −5,
−4, and −3 before the administration of a single
intravenous infusion of axi-cel at a target dose of
2×106 CAR T cells per kilogram of body weight
(on day 0).21 Systemic bridging chemotherapy was
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not allowed after leukapheresis and before the
administration of axi-cel. Patients who had an
initial response and then had disease progression
at least 3 months after the first dose of axi-cel
could be retreated.

rank-sum test to measure the associations between
outcomes and levels of CAR T cells and cytokines,
with P values adjusted using Holm’s procedure.
Confidence intervals were calculated with the use
of the Clopper–Pearson method.

End Points and Assessments

The primary end point was the rate of objective
response (calculated as the combined rates of complete response and partial response), as assessed by
the investigators according to the International
Working Group Response Criteria for Malignant
Lymphoma.23 Secondary end points included the
duration of response, progression-free survival,
overall survival, incidence of adverse events, and
blood levels of CAR T cells and serum cytokines.
The cytokine release syndrome was graded according to the criteria of Lee et al.24 We used the
National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.03, to grade
symptoms of the cytokine release syndrome and
neurologic events along with other adverse events.
CAR T-cell expansion and serum cytokines, and
their associations with clinical outcomes, were
analyzed as described previously.21,25 The cell-oforigin subtype was assessed centrally by means
of the NanoString Lymphoma Subtyping Test.26
Details regarding the response criteria, grading of
the cytokine release syndrome, and calculation
of the CD19 histologic score are provided in the
Methods section in the Supplementary Appendix.
Statistical Analysis

The primary analysis was conducted at the point
when 92 patients could be evaluated 6 months
after the axi-cel infusion. Efficacy and safety
analyses were reported in the modified intentionto-treat population of all the patients who had
received axi-cel. We also performed an updated
analysis of all the patients who had been treated
in phase 121 and phase 2 of ZUMA-1.
To analyze the response rate, we used a singlegroup design in which we compared the response
of patients with a prespecified rate of response
of 20% on the basis of historical values for refractory diffuse large B-cell lymphoma.4-12 Efficacy
testing had a power of at least 90% to distinguish
between an active therapy with a 40% true response rate and a therapy with a response rate
of 20% or less with the use of a one-sided alpha
level of 0.025. The primary end point was tested
with an exact binomial test. We used the Wilcoxon
n engl j med 377;26

R e sult s
Patients

A total of 111 patients were enrolled in the study.
Axi-cel was manufactured for 110 patients (99%)
and administered to 101 patients (91%); the latter
population was included in the modified intention-to-treat analysis. Patients included 77 with
diffuse large B-cell lymphoma and 24 with primary mediastinal B-cell lymphoma or transformed
follicular lymphoma (Table 1, and Fig. S1 in the
Supplementary Appendix). The date of data cutoff
for the primary analysis was January 27, 2017; the
median follow-up was 8.7 months. The cutoff date
for the updated analysis was August 11, 2017,
which resulted in a median follow-up of 15.4
months.
The median time from leukapheresis to delivery of axi-cel to the treatment facility was 17 days.
Of the 10 patients who did not receive axi-cel,
1 had unsuccessful manufacture of the CAR T-cell
product, 4 had adverse events, 1 died from disease
progression, and 2 had nonmeasurable disease
before conditioning chemotherapy. After conditioning chemotherapy but before axi-cel infusion,
1 patient had sepsis and 1 died from multiple
factors with laboratory abnormalities suggestive
of the tumor lysis syndrome, gastrointestinal
bleeding and perforation, and disease progression.
Among the patients who were treated with
axi-cel, the median age was 58 years (range, 23
to 76). Most of the patients (85%) had stage III or
IV disease; 77% had disease that was resistant to
second-line or later therapies, 21% had disease
relapse after transplantation, 69% had received at
least three previous therapies, and 26% had a
history of primary refractory disease (Table 1).
Efficacy

Primary Analysis

At a minimum of 6 months of follow-up, the objective response rate among the protocol-specified
92 patients was 82% (95% confidence interval [CI],
72 to 89; P<0.001 for the comparison with a 20%
historical control rate); among these patients, the
complete response rate was 52% (Table S1 in the
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Supplementary Appendix). An additional 9 patients were enrolled and awaiting treatment at
the time that the 92nd patient received the axicel infusion. Among the 101 patients who received
axi-cel, the objective response rate was 82% (95%
CI, 73 to 89), with a 54% complete response rate
(Fig. 1A, and Fig. S2 in the Supplementary Appendix).
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The median time to response was rapid (1.0
month; range, 0.8 to 6.0). The median duration
of response was 8.1 months (95% CI, 3.3 to could
not be estimated). Response rates were consistent
across key covariates, including age, disease stage,
International Prognostic Index score at enrollment,
presence or absence of bulky disease, cell-oforigin subtype, and use of tocilizumab or gluco-

Table 1. Treatment Disposition and Baseline Characteristics of the Patients.*
Variable

Patients with
DLBCL

Patients with
PMBCL or TFL

All Patients

81

30

111

Treatment disposition
No. of patients enrolled
Treatment with axi-cel — no. (%)
Yes
No

77 (95)

24 (80)

101 (91)

4 (5)

6 (20)

10 (9)

Death before treatment†

1 (1)

2 (7)

3 (3)

Adverse event‡

3 (4)

2 (7)

5 (5)

0

2 (7)

2 (2)

77

24

101

0

77 (76)

Other§
Characteristics at baseline
No. of patients
Disease type — no. (%)
DLBCL

77 (100)

PMBCL

0

8 (33)

8 (8)

TFL

0

16 (67)

16 (16)

58 (25–76)

57 (23–76)

58 (23–76)

17 (22)

7 (29)

24 (24)

Age
Median (range) — yr
≥65 yr — no. (%)
Male sex — no. (%)

50 (65)

18 (75)

68 (67)

ECOG performance-status score of 1
— no. (%)

49 (64)

10 (42)

59 (58)

I or II

10 (13)

5 (21)

15 (15)

III or IV

67 (87)

19 (79)

86 (85)

0–2

40 (52)

13 (54)

53 (52)

3 or 4

37 (48)

11 (46)

48 (48)

Disease stage — no. (%)

International Prognostic Index score
— no. (%)¶

CD-19 status — no./total no. (%)‖
Negative

7/63 (11)

1/19 (5)

8/82 (10)

Positive

56/63 (89)

18/19 (95)

74/82 (90)

Prior therapies — no. (%)

2534

≥Three prior lines of therapy

49 (64)

21 (88)

70 (69)

History of primary refractory disease**

23 (30)

3 (12)

26 (26)

History of resistance to two consecutive lines

39 (51)

15 (62)

54 (53)
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Table 1. (Continued.)
Patients with
DLBCL

Variable

Patients with
PMBCL or TFL

All Patients

Refractory subgroup at study entry — no. (%)
Primary refractory

2 (3)

0

2 (2)

Refractory to second-line or subsequent
therapy

59 (77)

19 (79)

78 (77)

Relapse after autologous stem-cell transplantation

16 (21)

5 (21)

21 (21)

*	The abbreviation axi-cel denotes axicabtagene ciloleucel, DLBCL diffuse large B-cell lymphoma, ECOG Eastern
Cooperative Oncology Group, PMBCL primary mediastinal large B-cell lymphoma, and TFL transformed follicular
lymphoma.
†	Two patients died from disease progression (one after unsuccessful manufacture of the CAR T-cell product) and one
from the tumor lysis syndrome.
‡	The adverse events in the four patients who had undergone leukapheresis but had not received conditioning therapy
or axi-cel were small intestine obstruction, hypoxia and pleural effusion, spinal column stenosis, and deep-vein
thrombosis. The remaining patient received conditioning therapy but had a skin and wound infection that led to ecthyma and sepsis before axi-cel treatment.
§	The two patients in this category had nonmeasurable disease after leukapheresis.
¶	Scores on the International Prognostic Index include low risk (0 or 1 point), low-intermediate risk (2 points), highintermediate risk (3 points), and high risk (4 or 5 points).
‖	The CD19 histologic score was assessed in the 82 patients with available samples.
**	Patients may have had other therapies after primary refractory disease.

corticoids. Responses were also consistent in 26
patients who had a history of primary refractory
disease (response rate, 88%) and in 21 patients
who had a history of autologous stem-cell transplantation (response rate, 76%). The response
rates did not appear to be influenced by biologic
covariates, such as the prevalence and intensity
of CD19 expression, or by product characteristics, such as the ratio of CD4 cells to CD8 cells
and T-cell phenotypes (Fig. 1B, and Tables S2,
S3, and S4 in the Supplementary Appendix).
At the time of the primary analysis, 52 patients
had disease progression, 3 patients had died from
adverse events during treatment, 1 patient started
an alternative therapy before disease progression, 44 remained in remission (of whom 39 had
a complete response), and 1 had stable disease.
Of the patients who had disease progression after
an initial response, 9 were retreated with axi-cel,
according to the protocol. Of these patients, 5 had
a response (2 complete and 3 partial), and 2 of
these patients had an ongoing response.
Updated Analysis

To evaluate the durability of response with axi-cel,
we performed an updated analysis when the 108
patients in the phase 1 and 2 portions of ZUMA-1
had been followed for a minimum of 1 year. The
objective response rate was 82%, including a comn engl j med 377;26

plete response rate of 58%. Of the patients who
did not have a complete response at the time of
the first tumor assessment (1 month after the
infusion of axi-cel), 23 patients (11 of 35 with a
partial response and 12 of 25 with stable disease)
subsequently had a complete response in the absence of additional therapies as late as 15 months
after treatment. At the data cutoff, 42% remained
in response, including 40% with a complete response. Of the 7 patients in phase 1 of the study,
3 had an ongoing complete response at 24 months.
Preliminary analysis of CD19 expression at
baseline and at the time of disease progression was
ongoing. Of the 11 patients with disease progression who were included in the analysis, 3 (27%)
with CD19-positive status at baseline had CD19negative disease at time of disease progression.
Ongoing response rates were consistent across
key covariates, including the use of tocilizumab
or glucocorticoids (Fig. S3 in the Supplementary
Appendix). The median duration of response was
11.1 months (95% CI, 3.9 to could not be estimated) (Fig. 2A). The median duration of progression-free survival was 5.8 months (95% CI,
3.3 to could not be estimated) (Fig. 2B), with progression-free survival rates of 49% (95% CI, 39 to
58) at 6 months, 44% (95% CI, 34 to 53) at 12
months, and 41% (95% CI, 31 to 50) at 15 months.
The median overall survival was not yet reached
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A Objective Response Rate
100
90

Best Response (%)

80

Complete response
83

82

Partial response

82

Stable disease

70
60
50

Disease progression
49
(38)

71
(17)

40
30
20
10
0

32
(25)
ORR

12
(9)
SD

5
(4)
PD

1
(1)

12
(3)
ORR

NE

DLBCL (N=77)

Could not be evaluated

54
(55)

8
(2)
SD

4
(1)

4
(1)

28
(28)

PD

NE

ORR

PMBCL or TFL (N=24)

11
(11)
SD

5
(5)

2
(2)

PD

NE

All Patients (N=101)

B Subgroup Analysis
Subgroup
Overall
Refractory subgroup
Refractory to ≥second-line therapy
Relapse after ASCT
Age
<65 yr
≥65 yr
Disease stage
I or II
III or IV
IPI risk score
0–2
3 or 4
Extranodal disease
Yes
No
Bulky disease (≥10 cm)
Yes
No
Treatment history
Primary refractory disease
Refractory to two consecutive lines
CD19 status
Positive
Negative
CD19 histologic score
≤150
>150
Cell of origin
Germinal center B-cell–like subtype
Activated B-cell–like subtype
CD4:CD8 ratio
>1
≤1
Tocilizumab use
Yes
No
Glucocorticoid use
Yes
No

No. of Patients
Who Could
Be Evaluated

No. of Patients
with Event

Objective Response Rate (95% CI)

101

83

0.82 (0.73–0.89)

78
21

65
16

0.83 (0.73–0.91)
0.76 (0.53–0.92)

77
24

61
22

0.79 (0.68–0.88)
0.92 (0.73–0.99)

15
86

13
70

0.87 (0.60–0.98)
0.81 (0.72–0.89)

53
48

46
37

0.87 (0.75–0.95)
0.77 (0.63–0.88)

70
31

56
27

0.80 (0.69–0.89)
0.87 (0.70–0.96)

17
84

12
71

0.71 (0.44–0.90)
0.85 (0.75–0.91)

26
54

23
42

0.88 (0.70–0.98)
0.78 (0.64–0.88)

74
8

63
6

0.85 (0.75–0.92)
0.75 (0.35–0.97)

26
56

22
47

0.85 (0.65–0.96)
0.84 (0.72–0.92)

49
17

43
13

0.88 (0.75–0.95)
0.76 (0.50–0.83)

47
52

41
40

0.87 (0.74–0.95)
0.77 (0.63–0.87)

43
58

36
47

0.84 (0.69–0.93)
0.81 (0.69–0.90)

27
74

21
62

0.78 (0.58–0.91)
0.84 (0.73–0.91)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Objective Response Rate
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Figure 1 (facing page). Objective Response Rate
among the 101 Treated Patients.
Panel A shows the objective response rate (ORR; calculated as complete response [CR] plus partial response [PR]) among the patients who received axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric
antigen receptor T-cell therapy, as well as the response
among the patients with stable disease (SD), disease
progression (PD), and those who could not be evaluated (NE). The patients in the modified intention-totreat population were evaluated according to the two
main disease cohorts: diffuse large B-cell lymphoma
(DLBCL) and either primary mediastinal large B-cell
lymphoma (PMBCL) or transformed follicular lymphoma (TLF). The numbers in parentheses indicate the
number of patients who had the specified response.
On independent central review, the objective response
rate was 71%, including a complete response rate of
51% and a partial response rate of 20%. Panel B
shows the subgroup analysis of the objective response
rate for key baseline and clinical covariates. Scores on
the International Prognostic Index (IPI) include low
risk (0 or 1 point), low-intermediate risk (2 points),
high-intermediate risk (3 points), and high risk (4 or
5 points). The 95% confidence interval (CI) was calculated with the use of the Clopper–Pearson method.
ASCT denotes autologous stem-cell transplantation.

(95% CI, 12.0 months to could not be estimated)
(Fig. 2C), with overall survival rates of 78% (95%
CI, 69 to 85) at 6 months, 59% (95% CI, 49 to 68)
at 12 months, and 52% (95% CI, 41 to 62) at 18
months. A total of 56% of patients remained alive
at the time of the data cutoff. Two patients who
had a response underwent allogeneic stem-cell
transplantation.
Safety

Primary Analysis

During treatment, all 101 patients who had received axi-cel had adverse events, which were grade
3 or higher in 95% (Table 2). The most common
adverse events of any grade were pyrexia (in 85%
of the patients), neutropenia (in 84%), and anemia (in 66%). The most common adverse events
of grade 3 or higher were neutropenia (in 78%),
anemia (in 43%), and thrombocytopenia (in 38%).
The cytokine release syndrome occurred in 94
patients (93%). Most cases were of low grade (37%
of grade 1 and 44% of grade 2), with 13% of grade
3 or higher (9% of grade 3, 3% of grade 4, and
1% of grade 5).
The most common symptoms of the cytokine
release syndrome of grade 3 or higher were py-

n engl j med 377;26

rexia (in 11% of the patients), hypoxia (in 9%),
and hypotension (in 9%). Vasopressors were used
in 17% of the patients. The median time after
infusion until the onset of the cytokine release
syndrome was 2 days (range, 1 to 12), and the
median time until resolution was 8 days. All the
events associated with the cytokine release syndrome resolved except for one event of grade 5
hemophagocytic lymphohistiocytosis. Another
event of grade 5 cardiac arrest occurred in a
patient with the cytokine release syndrome.
Neurologic events occurred in 65 patients (64%);
28% were grade 3 or higher. The most common
neurologic events of grade 3 or higher were encephalopathy (in 21% of the patients), confusional
state (in 9%), aphasia (in 7%), and somnolence (in
7%). Early neurologic signs included word-finding
difficulties (dysphasia), attention or calculation
defects (counting backward by serial 7s), and difficulty executing complex commands (handwriting).27 The median onset of neurologic events
occurred on day 5 (range, 1 to 17), with median
resolution on day 17 after infusion. One patient
had ongoing grade 1 memory impairment that resolved after the data cutoff for the primary analysis. All the other neurologic events resolved except
for four events, which were ongoing at the time
of death (two deaths from progressive disease
and two from adverse events unrelated to neurologic events). Rates of the cytokine release syndrome and neurologic events decreased over the
course of the study (Table S5 in the Supplementary Appendix). Forty-three percent of patients
received tocilizumab and 27% received glucocorticoids for the management of the cytokine release syndrome, neurologic events, or both,24 with
no apparent effect on overall or ongoing response
rates (Fig. 1B, and Fig. S3 in the Supplementary
Appendix).
Updated Analysis

Ten patients had serious adverse events (including nine infections in 8 patients) after the data
cutoff for the primary analysis (Table S6 in the
Supplementary Appendix). There were no new
events associated with the cytokine release syndrome or neurologic events related to axi-cel treatment. Forty-four patients (44%) died from causes
that included disease progression (in 37 patients),
adverse events (in 3 patients, including 2 with the
above-mentioned axi-cel–related events associated
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Figure 2 (facing page). Kaplan–Meier Estimates of the
Duration of Response, Progression-free Survival, and
Overall Survival.
Panel A shows the duration of response, according to
investigator assessment, in the 89 study patients who
had an objective response, including those with a complete response and those with a partial response. Patients who had a complete response had a longer duration of response than those with an objective or partial
response. According to independent central review, the
median duration of response was 8.1 months (range,
3.5 to could not be estimated [NE]). Panel B shows the
rate of progression-free survival, and Panel C the rate
of overall survival in the 108 patients who were treated
in the phase 1 and phase 2 studies. Tick marks indicate the time of data censoring at the last follow-up.
NR denotes not reached.

with the cytokine release syndrome and 1 with
pulmonary embolism that was not related to axicel), and other causes after disease progression
and subsequent therapies that were not related to
axi-cel (in 4). One death that was not associated
with axi-cel was previously reported in phase 1 of
ZUMA-1.21 There were no new deaths from adverse events after the primary analysis. No cases
of replication-competent retrovirus or axi-cel treatment-related secondary cancers were reported.
Biomarkers

CAR T levels peaked in the peripheral blood
within 14 days after infusion of axi-cel and were
detectable in most patients at 180 days after infusion (Fig. 3A). Three patients with ongoing
complete remission at 24 months still had detectable CAR T levels in the blood. Expansion was
significantly associated with response (P<0.001),
with an area under the curve within the first 28
days after treatment that was 5.4 times as high
among the patients who had a response as among
those who did not have a response. Peak expansion and area under the curve were significantly
associated with neurologic events of grade 3 or
higher but not with the cytokine release syndrome
(Fig. 3B, and Table S7 and Fig. S4 in the Supplementary Appendix). Of 44 serum biomarkers
that were examined, several biomarkers, including interleukin-6, -10, -15, and -2Rα and granzyme
B, were significantly associated with neurologic
events and the cytokine release syndrome of
grade 3 or higher (Table S8 in the Supplementary
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Appendix). Several biomarkers, including interleukin-2, granulocyte–macrophage colony-stimulating factor (GM-CSF), and ferritin, were significantly associated only with neurologic events of
grade 3 or higher (Fig. 3C). The induction of antiCAR antibodies was not observed in any patient.

Discussion
In this multicenter, phase 2 trial of axi-cel therapy,
82% of the 101 patients with refractory large B-cell
lymphoma who were treated had an objective response, and 54% had a complete response. These
findings compare favorably with the results of
the recent SCHOLAR-1 study of existing therapies
for this disease, which showed an objective response rate of 26% and a complete response rate
of 7%.14 With a median follow-up of 15.4 months
in our study, responses were ongoing in 42% of the
patients, including in 40% who had a complete
response, with the emergence of a plateau in the
duration of the response curve at 6 months. Although most responses occurred in the first
month, 23 patients had a complete response as late
as 15 months. It would be reasonable to monitor
patients who did not have a complete response at
the first disease assessment and allow for an opportunity for an improved response, since consolidation with allogeneic stem-cell transplantation
comes with a high rate of treatment-related death
and would also ablate CAR T cells. The median
overall survival had not been reached, with an
overall survival rate at 18 months of 52%. Ongoing durable remissions have been observed in patients at 24 months. These results, combined with
the observation of ongoing long-term remissions
beyond 4 years in the previous National Cancer
Institute study,17 suggest that axi-cel provides substantial clinical benefit for patients with refractory
disease.
In our study, the responses to treatment, including ongoing ones, were consistent across key
covariates. Similar response rates were observed
in the 8 patients with CD19-negative disease as
in those with CD19-positive disease at baseline,
which suggests the potential limitations in CD19
detection rather than true CD19 negativity. Analyses of product characteristics, including the ratio
of CD4 cells to CD8 cells and T-cell phenotypes,
also showed similar outcomes, which further
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highlights the consistency in treatment effects
across clinical and biologic covariates. One limitation of our study is the lack of a planned, detailed analysis of molecular and cytogenetic characteristics. Prospective data are needed on the
influence of disease biology, such as double- and
triple-hit lymphomas, on outcomes with CAR
T-cell therapy.

of

m e dic i n e

To be successful, a personalized cell therapy
must be delivered in a safe and timely manner.
In this study, we confirmed the feasibility and
reliability of centralized manufacturing and coordination of leukapheresis procedures and shipping from multiple centers across the country.
The product was manufactured for 99% of the
enrolled patients and was administered to 91%.

Table 2. Adverse Events, the Cytokine Release Syndrome, and Neurologic Events Associated with Treatment.*
Event

Any Grade

Grade 1 or 2

Grade ≥3

number of patients (percent)
Adverse event
Any

101 (100)

5 (5)

96 (95)

Pyrexia

86 (85)

72 (71)

14 (14)

Neutropenia

85 (84)

6 (6)

79 (78)

Anemia

67 (66)

24 (24)

43 (43)

Hypotension

60 (59)

46 (46)

14 (14)

Thrombocytopenia

59 (58)

21 (21)

38 (38)

Nausea

59 (58)

59 (58)

0

Fatigue

52 (51)

50 (50)

2 (2)

Decreased appetite

50 (50)

48 (48)

2 (2)

Headache

47 (47)

46 (46)

1 (1)

Diarrhea

43 (43)

39 (39)

4 (4)

Hypoalbuminemia

41 (41)

40 (40)

1 (1)

Hypocalcemia

40 (40)

34 (34)

6 (6)

Chills

39 (39)

39 (39)

0

Tachycardia

39 (39)

37 (37)

2 (2)

Febrile neutropenia

35 (35)

4 (4)

31 (31)

Encephalopathy

34 (34)

13 (13)

21 (21)

Thrombocytopenia

59 (58)

21 (21)

38 (38)

Vomiting

34 (34)

33 (33)

1 (1)

Hypokalemia

33 (33)

30 (30)

3 (3)

Hyponatremia

33 (33)

23 (23)

10 (10)

Constipation

31 (31)

31 (31)

0

White-cell count decreased

31 (31)

2 (2)

29 (29)

Any

94 (93)

81 (80)

13 (13)

Pyrexia

77 (76)

66 (65)

11 (11)

Hypotension

41 (41)

32 (32)

9 (9)

Hypoxia

22 (22)

13 (13)

9 (9)

Tachycardia

21 (21)

20 (20)

1 (1)

Chills

20 (20)

20 (20)

0

Sinus tachycardia

8 (8)

8 (8)

0

Headache

5 (5)

5 (5)

0

Cytokine release syndrome
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Table 2. (Continued.)
Event

Any Grade

Grade 1 or 2

Grade ≥3

number of patients (percent)
Neurologic event
Any

65 (64)

37 (37)

28 (28)

Encephalopathy

34 (34)

13 (13)

21 (21)

Confusional state

29 (29)

20 (20)

9 (9)

Tremor

29 (29)

28 (28)

1 (1)

Aphasia

18 (18)

11 (11)

7 (7)

Somnolence

15 (15)

8 (8)

7 (7)

Agitation

9 (9)

5 (5)

4 (4)

Memory impairment

7 (7)

6 (6)

1 (1)

Mental-status change

6 (6)

4 (4)

2 (2)

*	Listed are adverse events that occurred in at least 30% of the patients, along with symptoms of the cytokine release
syndrome and neurologic events that occurred in at least 5% of the patients. The cytokine release syndrome was categorized according to a modified grading system proposed by Lee et al.24 Individual symptoms of the cytokine release
syndrome and neurologic events were graded according to the National Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.03.

The short 17-day median turnaround time was
critical for these patients with refractory large
B-cell lymphoma, who generally have rapidly
growing disease.
We found that axi-cel could be administered
safely at medical facilities that perform transplantation, even if such centers had no experience in
CAR T-cell therapy. Algorithms for the management of the cytokine release syndrome and neurologic events were effectively implemented. The
incidence of the cytokine release syndrome and
neurologic events of grade 3 or higher decreased
over the course of the study, possibly because of
increased experience at the study centers and a
protocol amendment allowing for earlier administration of tocilizumab or glucocorticoids.27 The
cytokine release syndrome and neurologic events
were generally reversible with no clinical sequelae.
With extended follow-up, there were no new unexpected serious adverse events and no new onset
of the cytokine release syndrome or neurologic
events related to CAR T cells. Furthermore, the
3% rate of death during treatment compares favorably with rates observed during allogeneic stemcell transplantation.28
CAR T-cell levels over the first 28 days of treatment correlated with an objective response. This
finding was consistent with prior single-institution trials of CAR T-cell therapy19,25 and strengthens the hypothesis that the presence of higher
n engl j med 377;26

CAR T-cell levels after infusion may further augment efficacy. Recent studies have shown intrinsic differences in CAR T cells that use CD28
rather than other costimulatory molecules, such
as 4-1BB,29,30 but it remains unclear whether either
costimulatory domain will confer differences in
activity or persistence in patients and whether such
responses are dependent on the tumor type.31
Therefore, optimization of CAR constructs and
manufacturing as well as combination strategies
with immunomodulatory agents are being explored.
Serum biomarker analysis confirmed associations of the presence of interleukin-6, -15, and
-2Rα, as well as other markers, with the cytokine
release syndrome of grade 3 or higher19,32-35 and
with neurologic events of grade 3 or higher.19,34
However, CAR T-cell levels and specific cytokines, including interleukin-2, GM-CSF, and ferritin, were associated only with grade 3 or higher
neurologic events, which suggests that distinct
mechanisms may underlie the pathogenesis of
these adverse events.
Although there is a theoretical concern regarding the use of immunosuppressive agents to
manage the cytokine release syndrome or neurologic events, the use of tocilizumab or glucocorticoids did not appear to affect the overall response
among the patients in our study. Furthermore, the
development of a predictive or prognostic early
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A CAR T-Cell Expansion
Day 7

102

CAR-Positive Cells
(no./µl)

101
Q3

100

Median
10−1
Q1
10−2
LOD

0

30

60

90

120

150

180

Days after Infusion

B Association between CAR T-Cell Expansion and Clinical Outcomes
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Objective No Objective
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Response
Rate
Rate
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C Serum Biomarkers Associated with Neurologic Events
Interleukin-2
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(N=73)

100
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biomarker of the cytokine release syndrome or
neurologic events may assist clinicians in determining when to intervene and optimize the
management of toxic effects while preserving
efficacy.
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Grade 0–2
Events
(N=73)

102

P=0.006

Grade ≥3
Events
(N=28)

Grade 0–2
Events
(N=73)

In conclusion, our findings support the use of
axi-cel as an effective therapeutic option in adult
patients with relapsed or refractory large B-cell
lymphoma after at least two prior systemic therapies. Adverse events included myelosuppression,
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Figure 3 (facing page). CAR T-Cell Expansion and
Correlations with Response and Adverse Events.
Serial blood samples were analyzed for chimeric antigen receptor (CAR) T-cell levels and serum biomarkers
in all 101 patients who were treated with axi-cel, as described previously.21 Panel A shows CAR T-cell expansion and persistence with median values and interquartile ranges (Q1 and Q3). Panel B shows the
association between CAR T-cell expansion, which was
measured as peak levels of CAR cells per microliter of
blood, and the objective response rate, neurologic
events, and the cytokine release syndrome. The peak
factor change is shown for patients with a response as
compared with those without a response, for those
with neurologic events of grade 3 or higher, and for
those with the cytokine release syndrome of grade 3
or higher. P values were calculated by means of the
Wilcoxon rank-sum test. Panel C shows serum biomarkers (interleukin-2, granulocyte–macrophage colony-stimulating factor [GM-CSF], and ferritin) that were
associated only with neurologic events and not with
the cytokine release syndrome. The peak value is defined as the maximum level of the cytokine after baseline. The peak factor is the value in patients with neurologic events of grade 3 or higher versus those with
events of grade 0 to 2. Adjusted P values were calculated with the use of Holm’s procedure after multiple
testing by means of the Wilcoxon rank-sum test. In
Panels B and C, the horizontal line within each box
represents the median, and the lower and upper borders of each box represent the 25th and the 75th percentiles, respectively, and the I bars represent the
minimum and maximum range.

the cytokine release syndrome, and neurologic
events.
Supported by Kite Pharma and the Leukemia and Lymphoma
Society Therapy Acceleration Program.
Dr. Neelapu reports receiving advisory board fees from Kite
Pharma; Dr. Locke, receiving consulting fees from Cellular Biomedicine Group and scientific advisory fees from Kite Pharma;
Dr. Bartlett, receiving grant support from Celgene, Genentech,
Merck, Bristol-Myers Squibb, Immune Design, Forty Seven, Affimed, Janssen, Pharmacyclics, Millennium, ImaginAb, Novar-

tis, Gilead, Dynavax, Medimmune, Incyte, and Idera and grant
support and advisory board fees from Seattle Genetics, Pfizer,
and Kite Pharma; Dr. Miklos, receiving grant support and advisory board fees from Kite Pharma, Pharmacyclics, Adaptive
Biotechnologies, Novartis, and Janssen; Dr. Jacobson, receiving
consulting fees from Kite Pharma; Dr. Braunschweig, receiving
lecture fees from Kite Pharma; Dr. Siddiqi, receiving grant support and lecture fees from Pharmacyclics, lecture fees from Seattle Genetics, and grant support and fees for serving on a
steering committee from Juno; Dr. Timmerman, receiving grant
support from Bristol-Myers Squibb, Valor Biopharmaceuticals,
and Janssen and consulting fees from Celgene, Seattle Genetics,
and Genmab; Dr. Friedberg, receiving fees for serving on an
advisory board from Bayer; Dr. Flinn, receiving grant support
from Acerta, Agios, ArQule, BeiGene, Calithera, Constellation,
Forty Seven, Genentech, Gilead, Infinity, Janssen, Kite Pharma,
Merck, Novartis, Pharmacyclics, Seattle Genetics, TG Therapeutics, Trillium Therapeutics, and Verastem; Dr. Goy, receiving
grant support, paid to his institution, consulting fees, and honoraria from Celgene and Pharmacyclics, grant support, paid to
his institution, and honoraria from Acerta, grant support, paid
to his institution, and consulting fees from Genentech, and
honoraria from Takeda; Dr. Smith, receiving grant support and
consulting fees from Seattle Genetics, consulting fees from Genentech, and grant support from Takeda and Celgene; Dr. Farooq, receiving grant support from Kite Pharma; Dr. McSweeney, receiving advisory board fees and lecture fees from Kite
Pharma; Dr. Munoz, serving on advisory boards for Pfizer,
Pharmacyclics, Alexion, and Bayer; Dr. Chavez, receiving lecture
fees from Kite Pharma and advisory board fees from Novartis;
Dr. Ghobadi, lecture fees from Kite Pharma; Dr. Levy, receiving
consulting fees from Five Prime, BeiGene, Innate Pharma, Immune Design, and Corvus and grant support from Bristol-Myers
Squibb, Pfizer, Pharmacyclics, and Dynavax; Dr. Jacobsen, receiving consulting fees from Bayer, Merck, Seattle Genetics,
Spectrum, and Pharmacyclics; Dr. Reagan, receiving grant support from Seattle Genetics; Drs. Bot, Jiang, Chang, Wiezorek,
and Go, Mr. Rossi, Ms. Navale, Mr. Aycock, and Ms. Elias, being
employed by Kite Pharma; Drs. Jiang and Wiezorek, Mr. Aycock,
and Ms. Elias, having an equity interest in Kite Pharma; Mr.
Rossi, Ms. Navale, and Dr. Go, having an equity interest in Gilead Sciences; and Dr. Chang, having an equity interest in Gilead
Sciences, Cell Design Lab, and UroGen. No other potential
conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank the patients who participated in the study and their
families, friends, and caregivers; the study staff and health care
providers at all the study sites; and Dustin Khiem of Kite Pharma
and Skye Geherin and Jennifer Leslie of Nexus Global Group
Science for medical writing.

Appendix
The authors’ full names and academic degrees are as follows: Sattva S. Neelapu, M.D., Frederick L. Locke, M.D., Nancy L. Bartlett, M.D.,
Lazaros J. Lekakis, M.D., David B. Miklos, M.D., Ph.D., Caron A. Jacobson, M.D., M.M.Sc., Ira Braunschweig, M.D., Olalekan O. Oluwole, M.B., B.S., M.P.H., Tanya Siddiqi, M.D., Yi Lin, M.D., Ph.D., John M. Timmerman, M.D., Patrick J. Stiff, M.D., Jonathan W.
Friedberg, M.D., M.M.Sc., Ian W. Flinn, M.D., Ph.D., Andre Goy, M.D., Brian T. Hill, M.D., Ph.D., Mitchell R. Smith, M.D., Ph.D.,
Abhinav Deol, M.D., Umar Farooq, M.D., Peter McSweeney, M.D., Javier Munoz, M.D., Irit Avivi, M.D., Januario E. Castro, M.D., Jason R. Westin, M.D., Julio C. Chavez, M.D., Armin Ghobadi, M.D., Krishna V. Komanduri, M.D., Ronald Levy, M.D., Eric D. Jacobsen,
M.D., Thomas E. Witzig, M.D., Patrick Reagan, M.D., Adrian Bot, M.D., Ph.D., John Rossi, M.S., Lynn Navale, M.S., Yizhou Jiang,
Ph.D., Jeff Aycock, B.A., Meg Elias, R.N., B.S.N., David Chang, M.D., Ph.D., Jeff Wiezorek, M.D., and William Y. Go, M.D., Ph.D.
The authors’ affiliations are as follows: the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis
(N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National
Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San
Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) — all in California; Dana–Farber
Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine,
Rochester (J.W.F., P.R.) — both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute

n engl j med 377;26

nejm.org

December 28, 2017

2543

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 18, 2018. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

Axicabtagene Ciloleucel in Large B-Cell Lymphoma

and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood,
IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland
(B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa
City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv
Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

References
1. Sehn LH, Gascoyne RD. Diffuse large
B-cell lymphoma: optimizing outcome in
the context of clinical and biologic heterogeneity. Blood 2015;125:22-32.
2. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require
a unique therapeutic approach? Blood
2015;125:33-9.
3. Casulo C, Burack WR, Friedberg JW.
Transformed follicular non-Hodgkin lymphoma. Blood 2015;125:40-7.
4. Ardeshna KM, Kakouros N, Qian W,
et al. Conventional second-line salvage
chemotherapy regimens are not warranted in patients with malignant lymphomas
who have progressive disease after firstline salvage therapy regimens. Br J Haematol 2005;130:363-72.
5. Hitz F, Connors JM, Gascoyne RD, et
al. Outcome of patients with primary refractory diffuse large B cell lymphoma
after R-CHOP treatment. Ann Hematol
2015;94:1839-43.
6. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of
primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is
there a chance for cure? J Clin Oncol
2000;18:332-9.
7. Matasar MJ, Czuczman MS, Rodriguez
MA, et al. Ofatumumab in combination
with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade Bcell lymphoma. Blood 2013;122:499-506.
8. Moskowitz CH, Bertino JR, Glassman
JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction
and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible
patients with non-Hodgkin’s lymphoma.
J Clin Oncol 1999;17:3776-85.
9. Nagle SJ, Woo K, Schuster SJ, et al.
Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma
with progression of lymphoma after autologous stem cell transplantation in the
rituximab era. Am J Hematol 2013;
88:
890-4.
10. Philip T, Guglielmi C, Hagenbeek A,
et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J
Med 1995;333:1540-5.
11. Seshadri T, Stakiw J, Pintilie M, Keating A, Crump M, Kuruvilla J. Utility of
subsequent conventional dose chemotherapy in relapsed/refractory transplanteligible patients with diffuse large B-cell
lymphoma failing platinum-based salvage

2544

chemotherapy. Hematology 2008;13:2616.
12. Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem
cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes
and prognostic factors. Leuk Lymphoma
2012;53:836-41.
13. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology
Am Soc Hematol Educ Program 2011;
2011:498-505.
14. Crump M, Neelapu SS, Farooq U, et
al. Outcomes in refractory diffuse large
B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;
130:1800-8.
15. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of
anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
16. Kochenderfer JN, Dudley ME, Kassim
SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent
B-cell malignancies can be effectively
treated with autologous T cells expressing
an anti-CD19 chimeric antigen receptor.
J Clin Oncol 2015;33:540-9.
17. Kochenderfer JN, Somerville RPT, Lu
T, et al. Long-duration complete remissions of diffuse large B cell lymphoma
after anti-CD19 chimeric antigen receptor
T cell therapy. Mol Ther 2017;25:2245-53.
18. Schuster S, Svoboda J, Nasta S, et al.
Sustained remissions following chimeric
antigen receptor modified T cells directed
against CD19 (CTL019) in patients with
relapsed or refractory CD19+ lymphomas.
Blood 2015;126:183.
19. Turtle CJ, Hanafi LA, Berger C, et al.
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and
CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med
2016;8:355ra116.
20. Kochenderfer JN, Feldman SA, Zhao
Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen
receptor. J Immunother 2009;32:689-702.
21. Locke FL, Neelapu SS, Bartlett NL, et
al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T
cell therapy in refractory aggressive lymphoma. Mol Ther 2017;25:285-95.
22. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th ed.
Geneva:World Health Organization, 2008.
23. Cheson BD, Pfistner B, Juweid ME, et
al. Revised response criteria for malig-

n engl j med 377;26

nejm.org

nant lymphoma. J Clin Oncol 2007;
25:
579-86.
24. Lee DW, Gardner R, Porter DL, et al.
Current concepts in the diagnosis and
management of cytokine release syndrome. Blood 2014;124:188-95.
25. Kochenderfer JN, Somerville RPT, Lu
T, et al. Lymphoma remissions caused by
anti-CD19 chimeric antigen receptor T
cells are associated with high serum interleukin-15 levels. J Clin Oncol 2017;35:
1803-13.
26. Scott DW, Wright GW, Williams PM,
et al. Determining cell-of-origin subtypes
of diffuse large B-cell lymphoma using
gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014;
123:
1214-7.
27. Neelapu SS, Tummala S, Kebriaei P, et
al. Chimeric antigen receptor T-cell therapy — assessment and management of
toxicities. Nat Rev Clin Oncol 2017 September 19 (Epub ahead of print).
28. Klyuchnikov E, Bacher U, Kroll T, et
al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant 2014;49:1-7.
29. Kawalekar OU, O’Connor RS, Fraietta
JA, et al. Distinct signaling of coreceptors
regulates specific metabolism pathways
and impacts memory development in CAR
T cells. Immunity 2016;44:380-90.
30. Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor
rejection kinetics and persistence of CAR
T cells. Cancer Cell 2015;28:415-28.
31. Park JH, Brentjens RJ. Are all chimeric antigen receptors created equal? J Clin
Oncol 2015;33:651-3.
32. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J
Med 2014;371:1507-17.
33. Davila ML, Riviere I, Wang X, et al.
Efficacy and toxicity management of 1928z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;
6:224ra25.
34. Turtle CJ, Hanafi LA, Berger C, et al.
CD19 CAR-T cells of defined CD4+:CD8+
composition in adult B cell ALL patients.
J Clin Invest 2016;126:2123-38.
35. Teachey DT, Lacey SF, Shaw PA, et al.
Identification of predictive biomarkers
for cytokine release syndrome after chimeric antigen receptor T-cell therapy for
acute lymphoblastic leukemia. Cancer
Discov 2016;6:664-79.
Copyright © 2017 Massachusetts Medical Society.

December 28, 2017

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 18, 2018. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

